Drugs / SL22P
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04556669 | Aug 2020 → Aug 2023 | cervical cancer, non-small cell lung carcinoma, sarcoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SL22P | “SL22P is a proprietary product of Senlang Biotechnology.” NCT04556669 ↗ |
| Modality | Cell therapy | “SL22P autologous CAR-T/CAR-TILs cells” NCT04556669 ↗ |